The Council on Ethics considers antimicrobial resistance (AMR) a material, systemic risk to both societies and investments, and has selected it as one of its focus areas for proactive engagement. Given the complexity of the problem, partnerships and sector-wide initiatives are key to tackling AMR and the Council on Ethics has therefore decided to join the Investor Action on Antimicrobial Resistance (IAAMR) which is organised by the Access to Medicine Foundation, the FAIRR Initiative and the UK Department of Health and Social Care. The objective of IAAMR is to leverage investor influence to combat drug-resistant superbugs. Read more here: Investor Action on Antimicrobial Resistance (amrinvestoraction.org)
